Cwestiwn ysgrifenedig WQ93502

Maintaining the continuity of supply of medicines to the UK is a reserved matter and is the responsibility of the UK Government. However, managing the implications of supply disruptions for the public and the NHS requires co-ordinated action between the UK and devolved governments, and the NHS.

There are currently supply disruptions affecting a number of insulin products, including Fiasp FlexTouch® (insulin aspart) and Tresiba FlexTouch ® (insulin degludec) 100units/ml solution in 3ml pre-filled pens. These are expected to be out of stock until January 2025.

Levemir InnoLet® and Insulatard InnoLet® 100units/ml suspension for injection in 3ml pre-filled pens have recently been discontinued by the manufacturer.

The disruption to the supply of these medicines is unsettling and worrying for those who have been prescribed them.

Medicines shortage letters have been issued for each of these, advising clinicians and community pharmacies of the actions, which need to be taken. Anyone who is having difficulty obtaining treatment should contact their doctor or pharmacist to discuss what alternatives might be available.

I issued a written statement on 18 October 2023 informing Members about the actions taken in the event of disruptions in the supply of medicines. Written Statement: Disruptions in the supply of medicines (18 October 2023) | GOV.WALES

The Welsh Government’s medicines shortages webpage has general advice about why shortages occur and how they are managed: https://www.gov.wales/medicines-shortages-0 and https://www.llyw.cymru/prinder-meddyginiaethau-0